Viewing Study NCT05732805

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:24 AM
Ignite Modification Date: 2026-03-02 @ 6:03 AM
Study NCT ID: NCT05732805
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-02-27
First Post: 2023-02-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Sponsor: Biocad
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
None Melanoma (Skin) View
None Melanoma Stage III View
None Melanoma Stage IV View
None Melanoma Unresectable View
None Melanoma Metastatic View
None Melanoma Advanced View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PD-1 View
None CTLA-4 View
None prolgolimab View
None nurulimab View
None immunotherapy View
None checkpoint inhibitors View
None CPI View
None programm death View
None cytotoxic T-lymphocyte-associated protein View